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Abstract
Background and Objectives Characterized by sudden onset
of severe joint pain, swelling, redness, and tenderness to
touch, gout ‘flare ups’ have a substantial impact on quality
of life (QoL). This research employed a patient-centered
approach to explore the symptoms and impacts of gout, and
assess the content validity of existing patient-reported
outcomes (PROs).
Methods Qualitative interviews were conducted with 30
US gout patients (non-tophaceous: n = 20, tophaceous: n =
10) and five expert rheumatologists. Each interview
included both concept elicitation (CE) questioning to learn
about the patient experience and cognitive debriefing to
assess the content validity of three PRO instruments (HAQ-
DI, GAQ, and TIQ-20). Nine of the patients provided
further real-time qualitative data through a smart phone
application. All qualitative data were subject to thematic
analysis using Atlas.ti. Two patient advisors and three
expert clinicians were engaged as advisors at key stages
throughout the research.
Results Interview and real-time data identified the same
core symptoms and proximal impact concepts. Severe pain
(typically in joints of extremities) was described as the
cardinal symptom, often accompanied by swelling, red-
ness, heat, sensitivity to touch, and stiffness. Domains of
QoL impacted included physical functioning, sleep, daily
activities, and work. The PRO instruments were generally
well-understood by patients, but each included items with
questionable relevance to at least some of the sample,
dependent on the specific joints affected.
Conclusions Gout patients experience severe pain in
affected joints, resulting in substantial limitations in
physical functioning. Both the HAQ-DI and the TIQ-20 are
useful for specific research purposes in the gout population,
although modifications are recommended.Electronic supplementary material The online version of this
article (doi:10.1007/s40271-016-0184-x) contains supplementary
material, which is available to authorized users.
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Keypoints for Decision Makers
A conceptual model was developed, based on
qualitative data, detailing the patient experience of
gout. A conceptual model can be critical in informing
the selection of optimal outcome assessments for
research studies and general clinical practice.
Pain was identified as being the cardinal, defining
symptom of gout, leading to a range of impacts on
health-related quality of life (HRQoL), most notably
physical functioning and sleep.
The HAQ-DI, the ‘overall concern’ GAQ domain,
and the TIQ-20 demonstrated some value for the
assessment of symptoms, impacts, and limitations in
gout, which highlights that there could be benefit
from developing a new measure specific to gout.
1 Background
Gout is among the most common inflammatory rheumatic
diseases of adulthood, affecting approximately 1–2 % of
adults in Western Europe [1] and 3.9 % of adults in the
USA [2]. With a higher incidence in men than women (3:1)
[2], the prevalence of gout is also rapidly increasing, with
an increase of 4 % per year reported in the UK alone [3].
Gout results from elevated or excess serum uric acid (SUA)
levels in the body [4], leading to the formation and depo-
sition of monosodium urate (MSU) crystals in the synovial
fluid and lining of joints and soft tissue [5, 6]. Shedding of
crystals into the synovial fluid of a peripheral joint (typi-
cally the first metatarsophalangeal joint, or ‘big toe’) typ-
ically triggers the first episode or ‘flare’ [7]. Other
commonly affected joints include the mid-tarsal joints,
ankles, knees, fingers, wrists, and elbows [5].
Flares are characterized by sudden onset of severe pain,
swelling, erythema, and tenderness to touch in the joint [8].
Without treatment, or through poor clinical management,
chronic tophaceous gout can develop, characterized by
chronic pain and stiffness, joint damage, and visibly evident
subcutaneous nodular deposits of MSU crystals (tophi) [5].
Only 10 % of the overall gout patient population are cur-
rently estimated to progress to chronic tophaceous gout [9].
While there is evidence that the symptoms experienced
during flares can substantially impact the health-related
quality of life of patients with gout [8], qualitative research
documenting the patient experience in depth is limited
[10, 11]. Gout has been reported to impact on mobility
(especially walking and climbing stairs), activities of daily
living (such as gardening and doing housework), emotional
functioning, sleep, and diet [12, 13], as well as work pro-
ductivity [10, 14]. A number of studies have demonstrated
that individuals with gout have lower physical functioning
than normative populations and study controls [8]. How-
ever, those existing studies are limited by the use of mostly
generic instruments to measure HRQoL, which arguably
lack the sensitivity to capture the full impact of the con-
dition, particularly in those with less severe gout [8].
Qualitative research can help provide a better under-
standing of the patient experience and overall health bur-
den of gout. Furthermore, the subsequent development of a
conceptual model detailing the experience from the patient
perspective could provide a starting point to aid selection
of appropriate clinical study endpoints or guide the
development of a new disease-specific measure. The ability
to effectively measure HRQoL is crucial for evaluating the
effects of the disease and treatment, as well as helping to
better understand the best approach to managing gout [15].
OMERACT (Outcome Measures in Rheumatology Clin-
ical Trials) recently published a report summarizing the
appropriateness of patient-reported outcomes (PROs) in
measuring impacts of chronic gout [16], based on assess-
ments of the OMERACT filters of truth (face, content, con-
struct and criterion validity), discrimination (reliability,
responsiveness), and feasibility (how easily the measure can
be applied given constraints of time, money, and inter-
pretability) [16]. Based on these criteria, OMERACT
endorsed the Health Assessment Questionnaire-Disability
Index (HAQ-DI) for use in assessing the physical impacts of
chronic gout [17]. Conversely, a gout-specific QoL measure
(Gout Assessment Questionnaire [GAQ]-v2.0) [18] was not
deemed appropriate because of several concerns, including
low internal consistency and construct validity [17]. Fol-
lowing publication of the OMERACT guidance, the Tophus
Impact Questionnaire (TIQ-20) was developed using quali-
tative interviews to assess tophi burden; its content validity
and psychometric validity have been established [19]. These
existing measures are either gout-specific or have been used
in gout populations. Nevertheless, it is essential to ensure all
concepts that are relevant and important to patients are
captured. The core domains relevant to assess in acute gout,
as identified by OMERACT, include pain, joint swelling,
joint tenderness, patient global assessment, and activity
limitations. For chronic gout, the core domains identified are
serum urate, acute gout attacks, tophus burden, HRQoL,
activity limitations, pain, and patient global assessment [12].
This study aimed to gain a strong understanding of gout
patients’ experiences of symptoms, flares, tophi burden,
and the broader impact of gout using a patient-centred
approach to inform development of a conceptual model.
Supplementary to traditional patient interviews, the study
employed novel digital methods to collect real-time qual-
itative data. Additionally, the content validity of three
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existing PROs in the specific context of use in gout pop-
ulations was assessed in accordance with the criteria out-
lined in the US FDA PRO guidance [20].
Throughout, a ‘patient-centric’ approach was taken. As
well as conducting patient interviews in a rigorous and
ethical fashion, this also involved two patient advisors
providing input and guidance as research partners rather
than being interviewed as ‘subjects’ [19, 21].
2 Methods
2.1 Overview of Study Methods
This was a qualitative, non-interventional interview study
involving 20 US patients with non-tophaceous gout, ten US
patients with tophaceous gout, and five expert
rheumatologists.
As illustrated in Fig. 1, three rounds of interviews, each
with ten patients were conducted: two rounds with patients
with non-tophaceous gout and a third with patients with
tophaceous gout. Interim analysis was conducted between
each round to allow for any potential revisions to the PROs
being evaluated. Following the interviews, nine of the
patients with non-tophaceous gout also took part in real-
time collection of qualitative data through a smart phone
application (‘app’).
To support a patient-centered approach and gain
clinical insight, two patient advisors and three of the
expert rheumatologists interviewed provided input and
guidance as research partners at key stages throughout
the research.
Fig. 1 Overview of study methodology for clinician and patient
interviews, digital collection of real-time qualitative data, and input
from patient advisors and clinical experts. CRF case report form,
GAQ Gout Assessment Questionnaire, HAQ Health Assessment
Questionnaire, ICF informed consent form, TIQ Tophus Impact
Questionnaire
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2.2 Qualitative Patient Data Collection
2.2.1 Recruitment
The patients were recruited via rheumatologists and pri-
mary care physicians in Baltimore, New Orleans, and St.
Louis, USA, in May/June 2014. Eligible patients had to be
aged C18 years, literate, fluent in English, have a physi-
cian-confirmed diagnosis of gout, and a history of flares
and/or tophi. Patients with tophaceous gout had to have at
least one measurable tophus on the hands/wrists and/or
feet/ankles measuring 5–20 mm in the longest diameter. A
purposive sampling approach was taken to ensure a range
of clinical and demographic characteristics.
2.2.2 Ethics
The study was approved and overseen by an Independent
Review Board in the US (approval codes: ADE1-14-472,
ADE2-14-168). Written informed consent was obtained
prior to the collection of any data.
2.2.3 Interview Process
Interviews lasted approximately 1.5 h. Detailed interview
guides were used by trained interviewers (see Supple-
mentary Table A in the Electronic Supplementary Material
[ESM] for an overview of the key questions included). The
patient advisors reviewed the interview guides and pro-
vided feedback on the language used, structure, and content
being covered.
The concept elicitation (CE) section of the interview
used open-ended exploratory questions to facilitate spon-
taneous and un-biased elicitation of content regarding the
patient experience of gout [22–24], followed by direct
focused questions if concepts of interest had not been fully
explored with patients.
The cognitive debriefing (CD) section of the interview
assessed the content validity of the HAQ-DI, the GAQ
‘overall concern’ domain (patients with non-tophaceous gout
only) and TIQ-20 (tophaceous gout only). A ‘think aloud’
approach [25, 26] was employed where patients shared their
thoughts and reasoning for selecting each response. Patients
were asked about their understanding of instructions and item
wording, the relevance of concepts captured, and the
appropriateness of response options and recall periods. All
interviews were audio-recorded and transcribed verbatim,
and identifiable information was removed.
2.2.4 Instruments
The HAQ-DI is a 20-item measure used in a range of pain
conditions [27, 28] to assess eight categories of physical
functioning: dressing, rising, eating, walking, hygiene,
reach, grip, and usual activities [29, 30]. All items employ
a response scale from zero (‘without any difficulty’) to
three (‘unable to do’). The HAQ-visual analog scale
(HAQ-VAS) is an anchored horizontal VAS scored from 0
(no pain) to 100 (severe pain) assessing severity of
arthritis-related pain [29, 30].
The GAQ ‘overall concern’ domain consists of 13 items
assessing the emotional impacts of gout [18, 31]. Although
OMERACT did not endorse the GAQ, the research team
felt the emotional impacts captured in the ‘overall concern’
domain were relevant and warranted exploration [17].
The TIQ-20 is a 20-item questionnaire assessing tophi
burden, developed and validated in a tophaceous gout
population; initial results demonstrated promising face and
construct validity, reproducibility, and feasibility [19]. The
TIQ-20, being specific to patients with tophi, was only
tested in the third round.
2.2.5 Digital Collection of Real-Time Qualitative Data
(RTQD)
Following interviews, half of the non-tophaceous gout
sample (n = 9) consented to also take part in additional
digital collection of real-time qualitative data (RTQD).
Logistical challenges meant RTQD were not collected in
the tophaceous gout sample; this is acknowledged as a
limitation. This method enhances ecological validity by
capturing data as patients go about their daily lives and at
the exact point where a symptom or impact is experienced,
in contrast with traditional interviews, where patients are
required to recall previous experiences in a formal setting
[20]. Given the nature of gout, whereby patients experience
fluctuations in the onset, frequency, and duration of signs/
symptoms (i.e. flares), this novel methodology allowed
patients to report on their experiences as and when flares
occurred rather than having to recall their experiences of
previous flares during a later interview. Data collected
through this medium arguably have stronger ecological
validity than data collected from an interview.
Patients were asked to download a research app (Field
Notes) to their smart phone. Six ‘tasks’ were devised by
the research team to generate insight into the patient
experience based on previous literature and open-ended
questions used in the patient interview guide. The tasks
were sent daily to patients via the app over a 7-day period
(see ESM 2). Patients responded by submitting images or
self-recorded videos via the app.
2.3 Clinician Interviews
Five English-speaking rheumatologists (from the US [n =
2], the UK, New Zealand, and Spain) who specialized in
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treating gout were identified via clinical networks and
participated in 60-min qualitative telephone interviews.
Questioning focused on the patient experience of gout,
symptoms/signs, and forms of treatments. Interviews were
conducted using a semi-structured interview guide and
were audio-recorded and transcribed verbatim.
2.4 Patient Advisors
As a patient-centered approach, two US English-speaking
patients with a clinician-confirmed diagnosis of non-
tophaceous gout provided input into the study design, the
patient interview guide, the conceptual model, the HAQ-
DI, the GAQ domain, and findings from round one of the
interviews with patients with non-tophaceous gout (n = 10).
The patient advisors were each engaged via teleconference
calls or presentations with the research team. Ideally, both
patient advisors would have been consulted in the same call
to facilitate more of a group discussion; unfortunately this
was not possible because of scheduling difficulties. The
patients were recruited via rheumatologists and primary
care physicians, and neither patient participated in the
qualitative interviews. Prior to involvement, the advisors
were provided with a training session on PROs and the
purpose of the study to give them the confidence to con-
tribute as collaborative active members of the research
team rather than being interviewed as ‘subjects’ [19, 21].
2.5 Clinician Advisors
Three of the rheumatologists interviewed also provided
guidance throughout the study by reviewing and providing
key clinical insights on study documents, the conceptual
model, and the full set of findings from the interviews with
patients with non-tophaceous gout (n = 20). As these
rheumatologists were also interviewed, they only provided
input on study documents and findings related to the patient
interviews, not the clinician interviews.
2.6 Qualitative Analysis of Interview Transcripts
Verbatim transcripts and video/audio recordings were
subject to thematic analysis and visual analysis [25, 32, 33]
using Atlas.Ti software [34]. Each transcript was assessed,
and patient comments pertaining to the research questions
were highlighted. A coding scheme was created and used
throughout the analysis process. New codes were organi-
cally added throughout coding. Conceptual saturation (i.e.,
the point at which no new concepts would emerge with
continued data collection [35]) was evaluated for the CE
component of the interviews. Saturation was evaluated by
dividing the tophaceous and non-tophaceous samples into
sets of equal numbers of transcripts (tophaceous: n = 2 in
each set; non-tophaceous: n = 5 in each set) and comparing
the concepts that emerged from each additional set of
transcripts. Saturation was considered achieved when no
new concepts emerged from analysis of subsequent
transcripts.
3 Results
3.1 Patient Sample Characteristics
All sampling quotas were achieved, ensuring patients with
a range of demographic and clinical characteristics were
recruited (Table 1). There was a higher proportion of males
than females, consistent with the ratio in the wider popu-
lation. Moreover, there was good representation of non-
Caucasians in both the non-tophaceous (45 % Caucasian;
55 % Black/African American) and the tophaceous (30 %
Caucasian; 70 % Black/African American) samples.
Patients with a wide range of educational levels were
included. For the RTQD collection, patients had to own a
certain type of smartphone.
Mean time since diagnosis was 6.8 years in the non-
tophaceous sample and 5 years in the tophaceous sample.
The non-tophaceous sample had marginally higher mean
SUA levels: 7.01 mg/dl compared with 6.6 mg/dl for the
tophaceous sample. Over half of patients with tophaceous
gout reported tophi on the ‘big toe’ (n = 70 %), with others
reported in the upper extremities, including the elbow (40
%), wrist (20 %), fingers (20 %), hand (10 %), and shoulder
(10 %).
3.2 Clinician Sample Characteristics
With one exception, all the expert clinicians interviewed
had been treating patients for 15–25 years, with caseloads
ranging from 100 to 230 patients per year, or 10–60
patients per month; one clinician was active in conducting
clinical rheumatology research but had stopped treating in
the prior year.
3.3 Patient Concept Elicitation (CE) Interviews
3.3.1 Flares
All patients apart from one recognized or demonstrated an
understanding of the term ‘‘flare’’ or ‘‘flare-up’’. Patients
similarly defined a flare with reference to pain, swelling,
and/or redness. Further detail is provided in Table 2.
The frequency of flares was reported as highly variable
in both samples (ranging from monthly to yearly occur-
rences) and dependent on the forms of treatment taken, if
any. Most patients with non-tophaceous gout (n = 12/15)
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Table 1 Summary of patient demographic characteristics
Description Non-tophaceous gout
interview sample (N = 20)
Qualitative RTDC
sample (N = 9)
Tophaceous
sample (N = 10)
Mean age, years (range) 59.3 (44–80) 57 (44–67) 52 (35–66)
Male sex 60 % (12) 55 % (5) 60 % (6)
Race
White 45 % (9) 45 % (4) 30 % (3)
Black/African American 55 % (11) 55 % (5) 70 % (7)
Ethnicity
Non-Hispanic or Latino 85 % (17) 67 % (6) 100 % (10)
No response 15 % (3) 33 % (3) –
Education
Some high school 15 % (3) 11 % (1) 10 % (1)
High school diploma or GED 20 % (4) 22 % (2) 10 % (1)
Some years of college 20 % (4) 22 % (2) 60 % (6)
Certificate program 5 % (1) 11 % (1) –
University/College degree or higher 40 % (8) 33 % (3) 20 % (2)
Work status
Working full or part-time 65 % (13) 67 % (6) 20 % (2)
Not working due to gout 15 % (3) 22 % (2) 10 % (1)
Retired 20 % (4) 11 % (1) 40 % (4)
Not working due to injury/disability/ caregiver for parent – – 30 % (3)
General health
Excellent 5 % (1) 11 % (1) –
Very good 15 % (3) 11 % (1) 10 % (1)
Good 55 % (11) 45 % (4) 60 % (6)
Fair 25 % (5) 33 % (3) 20 % (2)
Poor – – 10 % (1)
Approximate time since diagnosis date, mean (minimum, maximum) 6.79 y (10 mo, 33 y) 4.7 y (2, 15 y) 4.5 y (1 mo, 18 y)
Diagnostic criteria
Personal and family history 60 % (12) 44 % (4) 80 % (8)
Physical examination 95 % (19) 89 % (8) 100 % (10)
Blood test (serum uric acid) 95 % (19) 89 % (8) 100 % (10)
X-ray 15 % (3) 11 % (1) 40 % (4)
Synovial fluid examination 15 % (3) 33 % (3) 20 % (2)
Surgical removal of tophus – – 10 % (1)
Location of first gout attack (‘flare’)
First metatarsophalangeal joint 45 % (9) 11 % (1) 70 % (7)
Other mid-tarsal joint(s) 15 % (3) 11 % (1) –
Ankle(s) 25 % (5) 33 % (3) 20 % (2)
Knee 35 % (7) 33 % (3) 20 % (2)
Wrist 10 % (2) 11 % (1) 30 % (3)
Finger(s) 10 % (2) 22 % (2) 10 % (1)
Elbow(s) 5 % (1) – 20 % (2)
Other 30 % (6) 33 % (3) –
Foot 10 % (2) 11 % (1) –
Polyarticular and chronic tophaceous (stage 4) on presentation – – 10 % (1)
Approximate time since most recent attack, mean (minimum,
maximum)
1 y, 6 mo (6 mo, 9 y) 24.5 mo (10 mo,
10 y)
2.5 y (1 mo,
7.6 y)
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described their flares lasting just a few days (dependent on
promptly taking their medication, n = 4/15); in contrast,
five of the six patients with tophaceous gout described their
flares as lasting a week or longer.
Among patients with non-tophaceous gout, flares were
most commonly reported to occur in the toe (n = 5/10), foot
(n = 5/10), hands (n = 3/10), and ankles (n = 3/10). Simi-
larly, patients with tophaceous gout commonly reported
flares occurring in the feet (n = 4/7), hands (n = 3/7), elbow
(n = 3/7), and knee (n = 3/7).
The majority of patients with non-tophaceous gout who
talked about the onset of flares described them commonly
occurring, or being more noticeable, during the night (n =
7/15), while most patients with tophaceous gout specified
that flares occurred at any time of the day (n = 3/5).
All signs or symptoms experienced during flares are pre-
sented in Fig. 2. The signs and symptoms reported were
broadly similar across both patient samples, although a number
of symptoms were only reported by one or two of the patients
with tophaceous gout, such as skin damage and stinging.
The most commonly reported symptoms were joint pain,
swelling, and tenderness or sensitivity to touch. See
Table 3 for a summary of symptoms reported by over 30 %
of the non-tophaceous or tophaceous gout samples, with
example quotes.
3.3.2 Pain
All patients spontaneously reported experiencing severe
and debilitating pain during flares, most frequently
describing it as a ‘‘throbbing’’ sensation (non-tophaceous:
n = 8/20; tophaceous: n = 3/10). A number of patients
spoke metaphorically, three of whom described the pain to
be like a toothache: ‘‘You know how a toothache is? And it
just keeps throbbing and throbbing and aching and aching.
This is exactly what this feels like.’’ Others compared the
pain to childbirth, while one patient said the pain was so
severe he thought he had broken his toe.
Patients most often reported pain in the lower extremi-
ties, such as the foot (non-tophaceous: n = 12/20; topha-
ceous: n = 5/10), toe (non-tophaceous: n = 7/20;
tophaceous: n = 4/10), and/or knee (non-tophaceous: n =
6/20, tophaceous: n = 3/10). A subset of patients described
how the pain builds in the first phase of the attack and then
remains constant without subsiding until the episode is
over (non-tophaceous: n = 7/11; tophaceous: n = 6/6).
Patients talked about the duration of their pain within a
wide range of timeframes, ranging from days to weeks
(non-tophaceous: n = 18/20, tophaceous: n = 7/10).
3.3.3 Swelling
In total, 25 of the 30 patients (non-tophaceous: n = 16/20;
tophaceous: n = 9/10) described swelling as co-occurring
with other symptoms during a flare. Two patients described
the affected area swelling up to twice the normal size,
while others described it becoming ‘‘puffy’’ (n = 2),
looking ‘‘distorted’’/‘‘deformed’’ (n = 2) or getting a
‘‘lump’’ (n = 1). The swelling was reported to occur in the
same joints as the pain, with duration ranging from a day to
Table 1 continued
Description Non-tophaceous gout
interview sample (N = 20)
Qualitative RTDC
sample (N = 9)
Tophaceous
sample (N = 10)
Type of treatment currently receiving
Allopurinol 85 % (17) 78 % (7) 70 % (7)
Colchicine 35 % (7) 22 % (2) 20 % (2)
Uloric (febuxostat) 5 % (1) – 10 % (1)
Nonsteroidal anti-inflammatory drugs (NSAIDs) including
celebrex, prednisone, aleve, ibuprofen, indomethacin
15 % (3) 11 % (1) 50 % (5)
Pain relievers, including tylenol extra strength and tramadol 10 % (2) 11 % (1) –
Blood test (Serum uric acid) mg/dl, mean (range) 7.01 (3.5–11.9) 6.6 (3.5–11.9) 6.6 (2.7–11.1)
Blood test (SUA)
\6 mg/dl 40 % (8) 55 % (5) 40 % (4)
6–8 mg/dl 5 % (1) – 40 % (4)
[8.0 mg/dl 45 % (9) 33 % (3) 20 % (2)
Not recorded 10 % (2) 11 % (1) –
Data are presented as % (n) unless otherwise indicated
Location of first gout attack: some patients had a flare in more than one location. Type of treatment: some patients were receiving more than one
of the listed treatments. Blood test: majority of SUA results were recorded at time of diagnosis
GED general educational development, mo month, NSAID non-steroidal anti-inflammatory drug, RTDC real-time data capture, SUA serum uric
acid, y year
What Outcomes are Important for Gout Patients? In-Depth Qualitative Research 71
Table 2 Summary of concept elicitation findings on flares in both the non-tophaceous (n = 20) and tophaceous (n = 10) gout samples
Flares Patient sample Spontaneous Probed Summary and example quotes
Definition Non-tophaceous
(n = 20)
0 20 13/20 patients defined a flare as being when they experience pain/hurt (including
aching/throbbing): ‘‘Where that part of your body hurts, where it’s attacked it’’
Patients also talked about swelling (5/20), redness (3/20), and/or a tingle sensation (2/20)
Tophaceous
(n = 10)
4 4 6/8 patients defined a flare as being when they experience pain/hurt (including aching/
throbbing): ‘‘It’s—just very painful. My—my foot gets, um, red and inflamed and… like I said,
I can’t put any pressure on my foot. And I have constant thumping pain’’
Remaining patients talked about redness, inflammation/heat (2/8), and/or joint swelling (1/8)
Frequency Non-tophaceous
(n = 20)
7 11 Patients suggested the frequency of their flares was variable, ranging from monthly to a few
times a year: ‘‘I haven’t had a severe flare-up, uh, in my knees in probably a couple years
now’’
Tophaceous
(n = 10)
2 6 Patients suggested the frequency of their flares was variable, ranging from monthly to a few
times a year: ‘‘Maybe two or three times a year, not too bad though … I’m talking about
something that put me in the bed for a week… But before I got on the medicine, I imagine it—
it was a hell of a lot more than that’’
Duration Non-tophaceous
(n = 20)
2 13 12/15 patients reported their flares as mostly lasting a few days: ‘‘If I start taking the medication,
within, say, three days, it’s all gone. I usually have pretty much immediate relief, and within
three days, all traces of the flare-up are gone’’
3/15 mentioned that the duration was variable, lasting from a week to a month
Tophaceous
(n = 10)
3 3 5/6 patients specified that flares lasted for a week or longer: ‘‘And it stays for like definitely a
solid week. Or longer’’
1/6 specified that flares lasted a few days
Location Non-tophaceous
(n = 20)
10 0 Patients described flares across multiple locations: ‘‘I often experience more of the—the gout in
my right foot … but I do have it on the left side as well in my hands, worse than … my feet’’
Tophaceous
(n = 10)
6 1 Patients described flares across multiple locations: ‘‘Always—the hands and the arms is under
attack all the time. And the feet … It’s just like the lower extremities—and my hand’’
Timing Non-tophaceous
(n = 20)
8 7 7/15 discussed their flares occurring during the night: ‘‘Most of the time, it’s at night … once I
go to sleep and relax, I guess that’s when it really sets in, because I’m not as mobile’’
The remaining patients talked about flares occurring during the day (3/15), at any time (3/15) or
in the morning (2/15)
Tophaceous
(n = 10)
3 2 3/5 patients specified that flares occurred at any time or got worse through the day: ‘‘But I don’t
have the medicine on hand all the time, you know. And I never know when it’s going to
happen’’
2/5 said that flares occurred in the evening or at night
Fig. 2 Summary of symptoms and signs elicited from the non-tophaceous gout (n = 20) and tophaceous gout (n = 10) samples
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Table 3 Summary of concept elicitation findings for signs or symptoms reported by 30 % or more of the non-tophaceous (n = 20) or tophaceous
(n = 10) gout samples
Concept Patient sample Summary and example quotes
Total
(N = 30)
Non-
tophaceous
(N = 20)
Tophaceous
(N = 10)
Pain 30 (100 %) 20 (100 %) 10 (100 %) Patients described their pain in a way that depicted the severity: ‘‘my foot
had hurt so bad that I really thought I had twisted, sprained, or actually
pulled a ligament in my foot’’ (tophaceous gout)
Swelling 25 (83 %) 16 (80 %) 9 (90 %) Patients talked about swelling that occurred with pain: ‘‘Guess because the
swelling was like in the joint area, it—it made it difficult for… me to move
my toe along with the pain with the gout… And I guess with the pain and
the swelling I couldn’t wear any shoes’’ (tophaceous gout)
Tenderness or sensitivity to
touch
16 (53 %) 11 (55 %) 5 (50 %) Patients talked about tenderness of joints or joints being sensitive to touch:
‘‘it’s—can hardly touch it… it’s severe to that point where to touch it,
it’s… painful’’ (non-tophaceous gout)
Redness 13 (43 %) 8 (40 %) 5 (50 %) Patients talked about redness that occurred with the pain or swelling during a
flare: ‘‘well, it’s not a burn, but—like if somebody got a burn mark… and
you burned yourself, and it start bruising to the redness—that’s basically
what you see’’ (non-tophaceous gout)
Feeling ‘‘heat’’ or warmth
around the joint or burning
sensation
13 (43 %) 8 (40 %) 5 (50 %) Patients talked about experiencing ‘heat’ from the joint or the joint being
‘warm to touch’, and some described a burning sensation: ‘‘Because it feels
like it’s got a burn on it, but it doesn’t. So it’s like hot’’ (non-tophaceous
gout)
Tingling sensation 9 (30 %) 6 (30 %) 3 (30 %) Patients talked about tingling that was generally the initial sign or indication
of a flare starting: ‘‘the tingling comes when I—in the beginning… it’s like
letting me know—you going to be having a gout attack. And then I’ll start
taking the medicine, trying to subdue it’’ (tophaceous gout)
Aching 8 (27 %) 5 (25 %) 3 (30 %) Patients used the term ‘aching’ to describe their pain: ‘‘it’s a dull ache to the
point of— of distraction’’ (tophaceous gout)
Stiffness 8 (27 %) 5 (25 %) 3 (30 %) Patients reported stiffness in their affected joints: ‘‘like a stiffness, where I
can’t even—I got to like pull… my fingers… to pull them apart… almost
like they lock’’ (non-tophaceous gout)
Discomfort 6 (20 %) 6 (30 %) – Patients reported experiencing discomfort or ‘‘feeling uncomfortable’’ in
their affect joints: ‘‘Sometimes I develop, um, some pain—not pain, some
discomfort—in my foot if I’ve been out walking a long time, like on
concrete out shopping or whatever’’ (non-tophaceous gout)
Tightness 6 (20 %) 6 (30 %) – Patients talked about a general feeling of tightness or tightness in the
affected joints or tightness of the skin: ‘‘real tight and shiny and red’’
(non-tophaceous gout)
Inflamed joints 4 (13 %) – 4 (40 %) Patients mentioned that their joints or affected area becoming ‘‘inflamed’’
during a flare: ‘‘they’ll become aggravated, inflamed, burning’’
(tophaceous gout)
Cramping 4 (13 %) 1 (5 %) 3 (30 %) Patients used the term ‘cramping’ to describe their pain: ‘‘it feels like a
cramp coming on… with pain in the joint or whatever and then from there
just progress—the pain just progress’’ (tophaceous gout)
Physical functioning 30 (100 %) 20 (100 %) 10 (100 %) Patients most commonly described difficulty walking or limitation in
movement: ‘‘The degree of mobility was limited. It was almost to the point
where it seemed like my leg was stiff, and I couldn’t even bend it’’ (non-
tophaceous gout)
Sleep disturbance 28 (93 %) 18 (90 %) 10 (100 %) Patients discussed difficulty falling asleep as well being woken up from
sleep during the night (i.e., interrupted sleep) due to symptoms associated
with a flare: ‘‘if it’s flared up or whatever, it keeps me from sleeping. In
fact, if I lay on—if I sleep on my left side—this knee right here will—will
wake me up in pain’’ (tophaceous gout)
Daily activities or working life 28 (83 %) 18 (90 %) 10 (100 %) Patients most commonly reported choice of footwear being impacted,
hobbies and general daily activities/routine: ‘‘I couldn’t wear shoes. Um, I
would wear slippers, um, even if I went to the doctor’’ (non-tophaceous
gout)
Emotional/psychological
wellbeing
24 (80 %) 15 (75 %) 9 (90 %) Patients talked about a range of emotional impacts including feelings of
unhappiness or depression, worry, and irritation/frustration associated with
flares: ‘‘it kind of makes you depressed when you can’t get up and do your
normal activities that you’re used to doing—so it does make me a little
depressed over that ‘‘ (non-tophaceous gout)
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several months (non-tophaceous: n = 12/20; tophaceous:
n = 7/10).
3.3.4 Tenderness or Sensitivity to Touch
In total, 16 of the 30 patients (non-tophaceous: n = 11/20;
tophaceous: n = 5/10) talked about their joints feeling
tender or sensitive to touch: ‘‘I just can’t stand nothing to
touch it, don’t touch it.’’ A number of patients (non-
tophaceous: n = 6/10; tophaceous: n = 3/10) spontaneously
talked about the weight of a bed sheet on the affected area
being too painful to bear.
3.3.5 Signs or Symptoms Between Flares
In the non-tophaceous sample, six patients reported some
experience of signs or symptoms between flares, including
pain in affected joints (n = 3/6), swelling (n = 2/6), ten-
derness (n = 1/6), and discomfort (n = 1/6). However, these
symptoms were reported to be infrequent and less severe
than during a flare.
3.3.6 Tophi
All patients with tophaceous gout interviewed (n = 10)
discussed their tophi (or ‘‘knots’’, ‘‘nodules’’, ‘‘bumps’’, or
‘‘lumps’’), commonly located on the toe (n = 6/10) and/or
elbow (n = 5/10). Symptoms directly attributed to the tophi,
during or between flares, included pain (n = 7/10), soreness
(n = 3/10), and throbbing (n = 3/10). Two patients
described coping strategies to avoid bumping or knocking
the tophi as this would cause pain. However, four others
did not find their tophi bothersome. One patient talked
about people looking at his tophi, or feeling the need to
hide his tophi.
3.3.7 Triggers
Across both samples of patients, dietary triggers for gout
symptoms were commonly discussed, particularly red meat
(non-tophaceous: n = 13/20; tophaceous: n = 6/9), seafood
(non-tophaceous: n = 8/20; tophaceous: n = 8/9), and
alcohol (non-tophaceous: n = 6/20; tophaceous: n = 2/9).
Other triggers described by patients with tophaceous gout
included too much physical movement and past injury (n =
2/9, respectively).
3.3.8 Impacts
Patients described a number of QoL domains being
impacted: physical functioning, sleep, daily activities,
working life, emotional/psychological wellbeing, diet, and
social functioning (see Table 3).
Limitations in physical functioning, specifically gross
motor movements, were reported by all patients, including
difficulty walking (non-tophaceous: n = 18/20; tophaceous:
n = 9/10) and limitation in range of movement (non-topha-
ceous: n = 18/20; tophaceous: n = 9/10) due to the pain and
swelling that occurs particularly in the toe or foot. Patients also
reported difficulty exercising, arising, and climbing stairs.
Sleep disturbance was the second most commonly
reported impact, with most patients reporting difficulty
falling asleep or being woken up by the pain during flares
(non-tophaceous: n = 18/20; tophaceous: n = 10/10).
Impact of flares on their daily activities and working life
was also discussed (non-tophaceous n = 18/20, tophaceous
n = 10/10). Areas affected included work productivity
(non-tophaceous: n = 15/20; tophaceous: n = 9/10), choice
of footwear (non-tophaceous: n = 11/20; tophaceous: n =
3/10), and general daily routine (non-tophaceous: n =
10/20; tophaceous: n = 5/10).
Most patients (non-tophaceous: n = 15/20, tophaceous:
n = 9/10) described impacts on their emotional or psy-
chological well-being, notably, feelings of unhappiness/
depression (non-tophaceous: n = 11/20, tophaceous: n =
2/10) and irritation/frustration (non-tophaceous: n = 9/20,
tophaceous: n = 3/10) due to not being able to take part in
usual daily activities or plans. Patients described feeling
worried (non-tophaceous: n = 9/20, tophaceous: 6/10)
about when they would experience the next flare.
Table 3 continued
Concept Patient sample Summary and example quotes
Total
(N = 30)
Non-
tophaceous
(N = 20)
Tophaceous
(N = 10)
Diet 22 (73 %) 14 (70 %) 8 (80 %) Patients talked about the impact gout had on their diet, i.e., having to avoid
particular drinks/foods: ‘‘I try to keep myself out of danger by eating the
wrong food’’ (tophaceous gout)
Social functioning 15 (50 %) 9 (45 %) 6 (60 %) Patients talked about the impact their gout had on their family, as well as
having to miss or cancel plans: ‘‘It is a lot of stress on you because—
especially if you got things, you know, and my wife, if they let me going to
go—we going to do this. OK? Then that—I’ll wake up, and I can’t do it’’
(tophaceous gout)
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3.4 Saturation Analysis
Conceptual saturation was achieved in both patient groups,
with no new concepts emerging in the final set of inter-
views. For both patient groups, saturation was achieved
after eight interviews whereby no new concepts emerged in
any of the subsequent transcripts.
3.5 Digital Collection of RTQD
All core symptoms and proximal impact concepts emerged
from both the patient interviews and the digital collection of
RTQD. However, as the traditional interview methodology
enabled more direct probing, nine additional concepts were
elicited in comparison with the RTQD, including soreness,
throbbing sensation, redness, physical weakness, difficulty
bending down, difficulty with self-care tasks, difficulty
driving, irritation, and frustration. While the interviews
generally provided a greater depth of understanding
regarding the descriptions of key concepts and identifica-
tion of more distal concepts, the RTQD often brought the
data ‘to life’ and better conveyed the severity of symptoms
and impacts through visual imagery and spoken/written text
captured at the time the symptom and/or impact was
experienced. One patient sent a picture of his foot swelling
during a flare and explained in a video: ‘‘The picture shows
when the foot is inflamed and the swelling is so bad and it
hurts so bad you can’t even get up off the bed.’’ Another
patient recorded a video during the night when he was
woken by pain: ‘‘Another night when you can’t sleep be-
cause you’re in pain and your feet is inflamed with gout, it’s
very difficult… two in the morning, this pain is killing me.’’
3.6 Conceptual Model
A key aim of the CE questioning was to inform the devel-
opment of a conceptual model that comprehensively sum-
marises the symptoms and impacts experienced by patients
with gout (see Fig. 3). The model comprises all symptoms
and impacts reported by patients and clinicians in the
interviews. As presented in the model, symptoms were
considered to be concepts proximal to gout, with impacts
such as dietary or social functioning considered more distal.
The majority of symptoms and impacts were elicited by
both non-tophaceous and tophaceous patients. ‘Tophi’,
‘skin damage’, and ‘physical deformity’ were the only
concepts elicited only by patients with tophaceous gout.
3.7 Clinician CE Interviews
Findings from the five clinician interviews supported the
relevance of all symptoms and impacts elicited from patients
in the CE interviews and RTQD. Clinicians described flares
as self-defined by patients, of variable duration (longer
without treatment), of variable frequency and abrupt onset,
often worse at night or in the morning. Symptoms included
severe pain (n = 5/5), redness (n = 4/5), swelling (n = 4/5),
burning/warmth (n = 4/5), and tenderness/sensitivity to touch
(n = 2/5). Three clinicians suggested tophi are largely
asymptomatic unless physically touched and not overly
bothersome (n = 3/5). Patients’ emotional well-being, phys-
ical functioning, activities of daily living, sleep, and diet/
alcohol intake were considered most commonly impacted.
3.8 Patient Cognitive Debriefing (CD) Interviews
3.8.1 HAQ-DI
All patients (n = 30) were cognitively debriefed on the
HAQ-DI and HAQ-VAS pain scale. The instructions and
response options were generally well understood. Six
patients (five with non-tophaceous gout; one with topha-
ceous) felt the 7-day recall period was not long enough to
capture impacts of flares because of the variable frequency
of their flares. With the exception of two ‘aids and devices’
items (‘built up or special utensils’ and ‘long-handled
bathroom appliances’), all items were well understood and
completed without difficulty. However, only 12 of 34 items
were reported to be relevant by[50 % of the non-topha-
ceous sample (n = 20; see ESM 3). In contrast, 24 items
were relevant to C50 % of the tophaceous sample, reflecting
the greater functional impact of patients with tophaceous
gout (n = 10; see ESM 4). No concepts of importance were
reported to be missing by any of the patients.
The HAQ-VAS pain scale was well understood by all
patients and relevant to nearly all patients who were asked
(n = 10/11 patients).
3.8.2 ‘Overall Concern’ GAQ Domain
The 20 patients with non-tophaceous gout were cognitively
debriefed on the items in the ‘overall concern’ GAQ
domain. All items, the definition of a ‘gout attack’,
instructions, and response options provided in the GAQ
were well understood by all patients.
However, 7/13 items were not found to be relevant to
C50 % of the non-tophaceous sample (see ESM 5). The
lack of recall period also caused inconsistencies in the
patients’ responses (i.e., during flares only, or during and
between flares).
3.8.3 TIQ-20
The definition of a ‘gouty tophi’ was well understood by all
ten patients with tophaceous gout. Patient understanding of
item wording was also high. While 9/20 items were not
What Outcomes are Important for Gout Patients? In-Depth Qualitative Research 75
described as relevant by C50 % of patients (see ESM 6),
the concepts included in the TIQ-20 were reported by
patients during CE. With no recall period, patients were
unsure whether to consider only impacts of tophi experi-
enced during flares (where the impact was reported to be
greater) or whether to consider all impacts of their tophi.
3.9 Feedback from Expert Clinicians
Upon reviewing results from patient interviews, the expert
clinicians found the preliminary conceptual model was
consistent with their experience of treating patients with
non-tophaceous gout. Additionally, the three expert clini-
cians agreed with the CD findings for the HAQ-DI (notably
the lack of relevance in the non-tophaceous sample),
explaining that the HAQ-DI is generally used with more
severe or tophaceous gout that may limit physical func-
tioning in the upper extremities.
3.10 Patient Advisors
The patient advisors deemed the types of questions in the
interview guide to be relevant and worded appropriately.
All CE and CD findings resonated with the advisors. The
advisors confirmed the majority of items in the HAQ-DI
and HAQ-VAS were not relevant to their experience of
non-tophaceous gout that would flare in the lower
extremities rather than the hands.
4 Discussion
This study employed a patient-centered approach [19, 21]
to support the development of a conceptual model of gout
patients’ experiences of symptoms, management of gout
attacks (flares), tophi burden, and the broader impact of
gout. This was followed by evaluation of the adequacy of
existing PROs for measuring impacts from gout.
Consistent with the literature [8, 19, 36, 37], CE activ-
ities (both patient and clinician interviews and qualitative
digital ethnography) identified pain as being the cardinal,
defining symptom of gout, leading to a range of impacts on
QoL. In particular, this study found that patients discussed
severe debilitating flares of pain causing an inability to
weight bear and an impact on physical functioning (e.g.,
difficulty walking), sleep, daily activities, and work (e.g.,
Impacts
Psychological/Emoonal
Sleep
•Disturbed sleep
•Diﬃculty with bed sheets
• Sleeping more
Physical Funconing
•Diﬃculty gripping objects
•Diﬃculty geng up
• Inability to exercise
•Diﬃculty walking
•Diﬃculty climbing stairs 
• Limitaon in movement or 
acvity or unable to move
•Diﬃculty bending down
• Loss in balance
• Physical deformity 
Social Funconing
• Impact on friends, family or 
others: family taking care of them, 
diﬃculty doing things with the 
family, taking frustraon out on 
family/colleagues, inability to have 
sex
•Missing or changing plans
•Diﬃculty planning ahead
• Seek isolaon 
Avoidance 
Behaviours
•Avoid weight or 
pressure on foot
•Avoid being 
touched or bumped
Daily & Working Life
•Hobbies
• Self-care tasks
•Diﬃculty with footwear
• Impact on usual daily acvies 
or rounes (in general)
• Impact on work 
(producvity/me oﬀ work)
•Household chores
•Diﬃculty driving
Dietary
•Having to avoid eang certain 
foods
•Having to limit alcohol 
consumpon
• Loss of appete 
Note: Concepts in black text were elicited by both non-tophaceous and tophaceous gout paents. Concepts in orange text were reported by only 
non-tophaceous gout paents. Concepts in blue text were reported by only tophaceous gout paents.
Symptoms of gout (ﬂares)
Other signs and symptoms
• Redness
• Swelling
•Heat or warm to touch (or burning 
sensaon)
• Tingling
•Numbness 
• Sﬀness of joints
• Tightness (or ghtening up) 
• Physical weakness
• Tiredness
• Shortness of breath 
• Tophi 
• Bone/joint damage 
• Skin damage 
• Blood in urine
• Chills 
• Itching 
• Change in urine odor
• Yellow spots on skin
Pain symptoms
• Pain
• Soreness 
• Tenderness (or sensive to touch)
•Aching
• Throbbing sensaon
• Cramping
•Discomfort
• Snging
•Anxious
• Irritaon/aggravaon
• Frustraon
• Scared
•Unhappiness or depression
•Worry
• Self-blame 
• Feel panicked
• Feel helpless
•Annoyed, mad or angry
• Loneliness/isolaon
• Stress 
• Lose sense of me
• Self conscious
PROXIMAL DISTAL
Fig. 3 Conceptual model for both patients with non-tophaceous gout and those with tophaceous gout
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productivity) and social activities (e.g., missing/cancelling
plans). Such findings support a previous qualitative inter-
view study whereby pain, isolation, and work disability
were described as key impacts of gout [10]. Furthermore,
the findings are consistent with previous work that
specifically demonstrated the impact of gout on work and
productivity [10, 14]. The relationship between pain and
sleep, and the subsequent impact on QoL, is also well
documented in other pain conditions [38–40]. Interestingly,
despite being mentioned by almost all patients in this study
and as a key outcome identified in other qualitative studies,
sleep disturbance did not make it into OMERACT’s core
outcome domains for studies of acute and chronic gout
[12]. Tophi were not considered generally bothersome, but
were painful when knocked and impacted footwear choice.
The resulting conceptual model illustrates that the vast
majority of symptoms elicited from patients with topha-
ceous gout were also reported by those with non-topha-
ceous gout, aside from those specifically related to tophi,
such as skin damage. A model based on qualitative evi-
dence is of value to aid selection of the optimal outcomes
for monitoring, both in general clinical care and in clinical
research, and evaluating treatment efficacy. The added
value of digital RTQD should be considered in conjunction
with traditional patient interview methods when designing
future qualitative research [41]. While traditional patient
interviews remain the gold standard in exploring the patient
experience, qualitative data collected in real-time arguably
have stronger ecological validity and provide valuable
additional insights into the patient experience of non-
tophaceous gout; specifically the severity of symptoms and
impacts discussed. However, not all patients experienced
flares during the period of digital data collection, therefore
some concepts only emerged from the interviews.
CD findings and feedback from expert clinicians indi-
cated that the HAQ-DI lacks relevance in the non-topha-
ceous gout sample, predominantly because most items
assess impacts on physical functioning in the upper
extremities and fine motor movements as opposed to lower
extremities and gross motor movements. The HAQ-DI was
more relevant to the patients with tophaceous gout, who
were more likely to experience symptoms in the upper
extremities. These findings support previous literature [8]
and to some extent the OMERACT guidance to use the
HAQ-DI for assessing physical impacts of chronic gout
only, as the measure lacks sensitivity to capture the impact
of gout in those with less severe disease. However, the
findings also suggest potential value in developing a
measure of functioning specific to gout and relevant to both
patient groups that is less focused on the impact on upper
extremities/fine motor skills and has greater focus on the
lower extremities. The ability to effectively measure
HRQoL is critical for assessing treatment benefit in terms
of change over time and determining the best approach to
managing gout [15].
The majority of concepts captured in the GAQ domain
were reported to be too severe for patients with non-
tophaceous gout, suggesting the domain will have limited
value and is likely to have floor effects. The domain may
have value in a population of patients with poorer control
over their gout and who therefore potentially experience
stronger emotional impacts—but the responsiveness of the
instrument would need careful exploration.
CD findings for the TIQ-20 demonstrated conceptual
comprehensiveness in capturing impacts on functioning
specific to tophi. To capture the full impact of all gout
symptoms (and not just tophi-specific burden), it is rec-
ommended the measure is used in conjunction with an
instrument capturing wider functional impacts of gout.
Additionally, in terms of measuring a treatment interven-
tion, it may be useful to employ a response scale capturing
severity from 0 to 10 to clearly capture improvement rather
than an attitudinal scale (agree/disagree), and to clarify the
recall period.
5 Limitations and Future Research
While the patient advisors supported a ‘patient-centric’
approach [19, 21], only two advisors were engaged, the
views of whom may not represent the diversity of views
among the gout patient population. To capture a greater
breadth of experience, future research could include more
patient advisors. It is also important to note that, while
quantitative data have been reported in terms of the fre-
quency of concepts reported, the data are based on a small
number of patients, therefore limiting the generalizability
of the findings. Finally, it is acknowledged that real-time
data capture was only employed in the sample of patients
with non-tophaceous gout because of logistical challenges,
and future research could explore the added value of uti-
lizing this novel method in a sample of patients with
tophaceous gout.
6 Conclusions
In this qualitative interview study, a patient-centric
approach combined expert clinical input with patient
interviews and novel digital methods of qualitative data
collection to increase patient engagement and the ecolog-
ical validity of the data. The findings provide evidence that
the instruments evaluated have some value for the assess-
ment of patients with gout but also some limitations. These
shortcomings could be overcome with modifications or
through the development of a new measure capturing all
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functional impacts in both populations as guided by the
conceptual model.
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